Background: The and immunoproteasomegenes are essential in cell processes, such as decisions on cell survival or death, the cell cycle, and cellular differentiation. Because recent evidence has demonstrated an immunological role for proteasomes in various malignancies, including urothelial bladder carcinoma (UBC), we evaluated single nucleotide polymorphisms (SNPs) in and . We determined any associations between these SNPs and susceptibility to UBC in the Saudi community.
Methods: Samples of genomic DNA were taken from buccal cells of 111 patients with UBC and 78 healthy controls. TaqMan Real-Time PCR was used to determine genotype distributions and allele frequencies for the rs17587 G>A and rs2071543 G>T SNPs. We used SNPStats (https://www.snpstats.net) to choose each SNP's best interactive inheritance model.
Results: The rs17587 SNP was associated with the risk of UBC (odds ratio [OR] = 5.21, < 0.0001). In contrast, the rs2071543 SNP showed no association with UBC risk (OR = 1.13, = 0.7871). In terms of genotypic distribution, the rs17587 G>A SNP was more frequent in UBC cases than controls in both the dominant (OR = 7.5; 95% confidence interval, 3.7-15.1; = 0.0051) and recessive (OR = 17.11, 95% confidence interval 5.1-57.4; = 0.0026) models. Genotypic distribution of the rs2071543 G>T SNP was not significantly different between cases and controls in any interactive inheritance models ( > 0.05).
Conclusion: These results suggest a potential role for as a biomarker for increased UBC risk. Discovering more genetic variants within immunoproteasome genes related to antigen presentation could help further our understanding of this risk.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022703 | PMC |
http://dx.doi.org/10.7759/cureus.36293 | DOI Listing |
Cutaneous leishmaniasis (CL) is a significant public health problem leading to permanently disfiguring skin lesions caused by parasites. Lesion severity stems from an excessive host inflammatory response that prevents healing. Here, we characterized the transcriptional and translational responses of lymphatic endothelial cells (LECs) during murine CL using historical single-cell RNA sequencing data combined with flow cytometry and in vivo puromycin incorporation to assess translational activity.
View Article and Find Full Text PDFKidney Dis (Basel)
June 2024
Renal Division, Peking University First Hospital, Beijing, China.
Introduction: IgA nephropathy (IgAN) is a leading cause of end-stage renal disease. The exact pathogenesis of IgAN is not well defined, but some genetic studies have led to a novel discovery that the (immuno)proteasome probably plays an important role in IgAN.
Methods: We firstly analyzed the association of variants in the region with susceptibility to IgAN in 3,495 patients and 9,101 controls, and then analyzed the association between lead variant and clinical phenotypes in 1,803 patients with regular follow-up data.
Genes Immun
June 2024
Medical Immune Oncology Research Group (MIORG), Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.
Immune checkpoint therapies (ICT) for advanced solid tumors mark a new milestone in cancer therapy. Yet their efficacy is often limited by poor immunogenicity, attributed to inadequate priming and generation of antitumor T cells by dendritic cells (DCs). Identifying biomarkers to enhance DC functions in such tumors is thus crucial.
View Article and Find Full Text PDFBiomark Res
April 2024
Centre for Medical Sciences, University of Trento and Internal Medicine Division, Santa Chiara Hospital, Provincial Health Care Agency (APSS), Trento, Italy.
Background: Activation of CD28 on multiple myeloma (MM) plasma cells, by binding to CD80 and CD86 on dendritic cells, decreases proteasome subunit expression in the tumor cells and thereby helps them evade being killed by CD8 T cells. Understanding how CD28 activation leads to proteasome subunit downregulation is needed to design new MM therapies.
Methods: This study investigates the molecular pathway downstream of CD28 activation, using an in vitro model consisting of myeloma cell lines stimulated with anti-CD28-coated beads.
Circ Res
May 2024
Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (N.d.l.V., W.C., J.K., J.P.V.B., V.A., M.S., M.A., S.I.D., A.E.D., D.G.H., D.M.P.).
Background: Hypertension is characterized by CD8 (cluster differentiation 8) T cell activation and infiltration into peripheral tissues. CD8 T cell activation requires proteasomal processing of antigenic proteins. It has become clear that isoLG (isolevuglandin)-adduced peptides are antigenic in hypertension; however, IsoLGs inhibit the constitutive proteasome.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!